<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03225040</url>
  </required_header>
  <id_info>
    <org_study_id>AAAE5304</org_study_id>
    <nct_id>NCT03225040</nct_id>
  </id_info>
  <brief_title>Bone MicroArchitecture in Acromegaly</brief_title>
  <official_title>Cross-sectional Study of Bone Density, Bone Microarchitecture, Vertebral Fractures and Trabecular Bone Score in Patients With Acromegaly Treated With Pegvisomant Compared to Patients With Untreated Active Acromegaly</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will conduct a cross-sectional study of bone density, bone
      microarchitecture, vertebral fractures and trabecular bone score in 25 patients with
      acromegaly treated with Pegvisomant, the growth hormone (GH) receptor antagonist for at least
      1 year and with normal insulin-like growth factor-1 (IGF-1) levels. This study aims to
      describe the bone architecture and associated biochemical indices of bone turnover and
      metabolism in patients with active acromegaly and how these are altered with treatment of the
      disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Growth hormone (GH) and Insulin-Like Growth Factor-1 (IGF-1) are important regulators of bone
      modeling and remodeling, fundamental to maintenance of normal skeletal integrity. In
      acromegaly, a disease characterized by longstanding exposure to excess GH and IGF-1, these
      hormones induce marked skeletal changes. Most dual energy X-ray absorptiometry (DXA) studies
      report that bone mineral density (BMD) is normal in acromegaly. Despite this, however, there
      is mounting evidence that bone health is adversely affected in patients with both active and
      successfully treated acromegaly.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 3, 2016</start_date>
  <completion_date type="Anticipated">December 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Volumetric bone mineral density of radius (vBMD)</measure>
    <time_frame>Measured once at one study visit</time_frame>
    <description>Volumetric bone mineral density of radius (vBMD) measured by high resolution peripheral quantitative computed tomography (HR-pQCT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trabecular number of radius (TbN)</measure>
    <time_frame>Measured once at one study visit</time_frame>
    <description>HRpQCT determined bone microarchitecture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trabecular Thickness of radius (Tb.Th)</measure>
    <time_frame>Measured once at one study visit</time_frame>
    <description>HRpQCT determined bone microarchitecture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trabecular separation of radius (Tb.Sp)</measure>
    <time_frame>Measured once at one study visit</time_frame>
    <description>HRpQCT determined bone microarchitecture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortical density of radius</measure>
    <time_frame>Measured once at one study visit</time_frame>
    <description>HRpQCT determined bone microarchitecture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortical thickness of radius</measure>
    <time_frame>Measured once at one study visit</time_frame>
    <description>HRpQCT determined bone microarchitecture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Areal bone mineral density (aBMD) of lumbar sacral spine</measure>
    <time_frame>Measured once at one study visit</time_frame>
    <description>Areal bone mineral density of lumbar sacral spine determined by DXA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trabecular bone score of LS spine</measure>
    <time_frame>Measured once at one study visit</time_frame>
    <description>Trabecular bone score of lumbar sacral spine determined by DXA</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Acromegaly</condition>
  <condition>Osteoporosis Risk</condition>
  <arm_group>
    <arm_group_label>Acromegaly patients on pegvisomant</arm_group_label>
    <description>25 subjects with acromegaly on pegvisomant therapy with a normal IGF-1 level for at least 1 year.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegvisomant</intervention_name>
    <description>Subjects receiving pegvisomant as part of their clinical care for acromegaly will be studied.</description>
    <arm_group_label>Acromegaly patients on pegvisomant</arm_group_label>
    <other_name>Somavert</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral blood specimens
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        25 subjects with acromegaly on pegvisomant therapy with a normal IGF-1 level for at least 1
        year will be studied.

        Patients will be on stable doses of any pituitary hormone supplements for 3 months prior to
        study entry including gonadal steroid replacement for men or premenopausal women.
        Hypogonadal men and premenopausal women will be replaced with clinically appropriate sex
        steroid replacement. Subjects will be 50% females.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals with acromegaly

          -  On pegvisomant therapy with a normal IGF-1 level for at least 1 year

        Exclusion Criteria:

          -  Malignancy (except cured basal, squamous cell skin carcinoma or other cured cancers
             free from recurrence &gt; 3 years)

          -  Pregnancy or lactation within last 12 months

          -  Untreated primary hyperparathyroidism, hyper- or hypothyroidism

          -  Cushing's syndrome

          -  Prolactin-secreting pituitary adenoma

          -  GH deficiency

          -  On current drug therapy for osteoporosis

          -  Diabetes mellitus

          -  Renal insufficiency

          -  Liver disease

          -  Current or past use of glucocorticoids (more than physiologic dose), anticonvulsants,
             anticoagulants, methotrexate, aromatase inhibitors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pamela Freda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carlos Reyes-Vidal, MD</last_name>
    <phone>212-305-4921</phone>
    <email>csr52@columbia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pamela Freda, MD</last_name>
    <phone>212-305-2254</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Neuroendocrine Unit and Pituitary Center, Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela U. Freda, MD</last_name>
      <phone>212-305-2254</phone>
    </contact>
    <contact_backup>
      <last_name>Carlos M. Reyes-Vidal, MD</last_name>
      <phone>212-305-4921</phone>
      <email>csr52@cumc.columbia.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2017</study_first_submitted>
  <study_first_submitted_qc>July 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2017</study_first_posted>
  <last_update_submitted>July 19, 2017</last_update_submitted>
  <last_update_submitted_qc>July 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Pamela U. Freda</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Acromegaly</keyword>
  <keyword>Pegvisomant</keyword>
  <keyword>Osteoporosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Acromegaly</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

